Drug Shortage Report for VOLUVEN
Report ID | 137619 |
Drug Identification Number | 02278057 |
Brand name | VOLUVEN |
Common or Proper name | Voluven® (6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride injection) 500 mL |
Company Name | FRESENIUS KABI CANADA LTD |
Market Status | MARKETED |
Active Ingredient(s) | HYDROXYETHYL STARCH 130/0.4 |
Strength(s) | 6% |
Dosage form(s) | SOLUTION |
Route of administration | INTRAVENOUS INTRAVENOUS |
Packaging size | 500 mL |
ATC code | B05AA |
ATC description | BLOOD AND RELATED PRODUCTS |
Reason for shortage | Disruption of the manufacture of the drug. |
Anticipated start date | 2021-04-16 |
Actual start date | 2021-04-16 |
Estimated end date | 2021-07-01 |
Actual end date | 2021-06-23 |
Shortage status | Resolved |
Updated date | 2021-06-24 |
Company comments | Fresenius Kabi Canada Ltd. regrets to advise that due to a production delay, we will be encountering a supply interruption on our Voluven® 500 mL effective immediately until July 1st, 2021. Please note that our remaining inventory is short-dated with less than 1 month dating, and expires on April 30, 2021. Our Voluven® 250 mL and Volulyte® 500 mL formats are available for substitution. |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 165 GALAXY BLVD, SUITE 100 TORONTO, ONTARIO CANADA M9W 0C8 |
Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v8 | 2021-06-24 | English | Compare |
v7 | 2021-06-23 | French | Compare |
v6 | 2021-06-23 | English | Compare |
v5 | 2021-04-17 | English | Compare |
v4 | 2021-04-16 | French | Compare |
v3 | 2021-04-16 | English | Compare |
v2 | 2021-04-16 | French | Compare |
v1 | 2021-04-16 | English | Compare |
Showing 1 to 8 of 8